# A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

> **NCT04856930** · PHASE2 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 149 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **BIOLOGICAL:** Imsidolimab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04856930
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-07
- **Primary completion:** 2022-07-15
- **Final completion:** 2022-12-14
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04856930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04856930, "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04856930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*